Insider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Sells $157,088.16 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson sold 6,256 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $25.11, for a total transaction of $157,088.16. Following the transaction, the chief accounting officer now directly owns 19,241 shares of the company’s stock, valued at approximately $483,141.51. This represents a 24.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Travis Alvin Thompson also recently made the following trade(s):

• On Thursday, October 3rd, Travis Alvin Thompson sold 153 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $22.26, for a total value of $3,405.78.

Bicycle Therapeutics Trading Down 3.5 %

Shares of Bicycle Therapeutics stock opened at $21.79 on Friday. The company has a 50 day moving average of $24.62 and a 200-day moving average of $23.16. Bicycle Therapeutics plc has a 1-year low of $13.07 and a 1-year high of $28.67. The company has a market cap of $1.04 billion, a PE ratio of -6.62 and a beta of 0.89.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. During the same quarter in the prior year, the firm earned ($1.26) EPS. The firm’s revenue was down 50.0% compared to the same quarter last year. Research analysts forecast that Bicycle Therapeutics plc will post -3.01 earnings per share for the current year.

Institutional Trading of Bicycle Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Concurrent Investment Advisors LLC acquired a new position in shares of Bicycle Therapeutics during the first quarter valued at about $543,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Bicycle Therapeutics by 12.8% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 883,105 shares of the company’s stock valued at $21,989,000 after acquiring an additional 100,107 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in shares of Bicycle Therapeutics by 13.3% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,038,917 shares of the company’s stock worth $25,869,000 after purchasing an additional 121,613 shares during the period. Price T Rowe Associates Inc. MD raised its position in Bicycle Therapeutics by 45.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 401,646 shares of the company’s stock worth $10,001,000 after acquiring an additional 124,809 shares during the period. Finally, Baker BROS. Advisors LP raised its holdings in shares of Bicycle Therapeutics by 176.1% in the 1st quarter. Baker BROS. Advisors LP now owns 4,942,823 shares of the company’s stock worth $123,076,000 after purchasing an additional 3,152,433 shares during the period. 86.15% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BCYC has been the subject of several research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 target price on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. B. Riley lowered shares of Bicycle Therapeutics from a “buy” rating to a “neutral” rating and reduced their price target for the company from $33.00 to $28.00 in a research report on Wednesday, August 7th. Stephens assumed coverage on Bicycle Therapeutics in a report on Friday, November 8th. They set an “equal weight” rating and a $25.00 target price on the stock. JMP Securities reissued a “market outperform” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a report on Monday, September 16th. Finally, Oppenheimer reissued an “outperform” rating and set a $48.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $40.13.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.